The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT
Jan 1, 2017·,,,,,,,,,,,,,,,,,,,·
0 min read
Curtis R. Coughlin
Michael A. Swanson
Kathryn Kronquist
Cécile Acquaviva
Tim Hutchin
Pilar Rodríguez-Pombo
Marja-Leena Väisänen
Elaine Spector
Geralyn Creadon-Swindell
Ana M. Brás-Goldberg
Elisa Rahikkala
Jukka S. Moilanen
Vincent Mahieu
Gert Matthijs
Irene Bravo-Alonso
Celia Pérez-Cerdá
Magdalena Ugarte
Christine Vianey-Saban
Gunter H. Scharer
Johan L. K. Van Hove
Abstract
PURPOSE: The study’s purpose was to delineate the genetic mutations that cause classic nonketotic hyperglycinemia (NKH). METHODS: Genetic results, parental phase, ethnic origin, and gender data were collected from subjects suspected to have classic NKH. Mutations were compared with those in the existing literature and to the population frequency from the Exome Aggregation Consortium (ExAC) database. RESULTS: In 578 families, genetic analyses identified 410 unique mutations, including 246 novel mutations. 80% of subjects had mutations in GLDC. Missense mutations were noted in 52% of all GLDC alleles, most private. Missense mutations were 1.5 times as likely to be pathogenic in the carboxy terminal of GLDC than in the amino-terminal part. Intragenic copy-number variations (CNVs) in GLDC were noted in 140 subjects, with biallelic CNVs present in 39 subjects. The position and frequency of the breakpoint for CNVs correlated with intron size and presence of Alu elements. Missense mutations, most often recurring, were the most common type of disease-causing mutation in AMT. Sequencing and CNV analysis identified biallelic pathogenic mutations in 98% of subjects. Based on genotype, 15% of subjects had an attenuated phenotype. The frequency of NKH is estimated at 1:76,000. CONCLUSION: The 484 unique mutations now known in classic NKH provide a valuable overview for the development of genotype-based therapies.Genet Med 19 1, 104-111.
Type
Publication
Genet Med